Clinical Trial Update: Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating caffeine as an inhibitor of VAP-1 in healthy volunteers was withdrawn; the study was associated with liver disease in the conditions li…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• Caffeine (caffeine)

Snippet

Sponsor: University of Birmingham | Conditions: Liver Disease | Phase 1 | Status: WITHDRAWN